Literature DB >> 23289420

CXCR4 and CXCR7 form a functional receptor unit for SDF-1/CXCL12 in primary rodent microglia.

J Lipfert1, V Ödemis, D-C Wagner, J Boltze, J Engele.   

Abstract

AIMS: Microglial cells have been originally identified as a target for the CXC chemokine, SDF-1, by their expression of CXCR4. More recently, it has been recognized that SDF-1 additionally binds to CXCR7, which depending on the cell type acts as either a nonclassical, a classical or a scavenger chemokine receptor. Here, we asked whether primary microglial cells additionally express CXCR7 and if so how this chemokine receptor functions in this cell type.
METHODS: CXCR4 and CXCR7 expression was analysed in cultured rat microglia and in the brain of animals with permanent occlusion of the middle cerebral artery (MCAO) by either Western blotting, RT-PCR, flow cytometry and/or immunocytochemistry. The function of CXCR4 and CXCR7 was assessed in the presence of selective antagonists.
RESULTS: Cultured primary rat microglia expressed CXCR4 and CXCR7 to similar levels. Treatment with SDF-1 resulted in the activation of Erk1/2 and Akt signalling. Erk1/2 and Akt signalling were required for subsequent SDF-1-dependent promotion of microglial proliferation. In contrast, Erk1/2 signalling was sufficient for SDF-1-induced migration of microglial cells. Both SDF-1-dependent signalling and the resulting effects on microglial proliferation and migration were abrogated following pharmacological inactivation of either CXCR4 or CXCR7. Moreover, treatment of cultured microglia with lipopolysaccharide resulted in the co-ordinated up-regulation of CXCR4 and CXCR7 expression. Likewise, reactive microglia accumulating in the area adjacent to the lesion core in MCAO rats expressed both CXCR4 and CXCR7.
CONCLUSIONS: CXCR4 and CXCR7 form a functional receptor unit in microglial cells, which is up-regulated during activation of microglia both in vitro and in vivo.
© 2013 British Neuropathological Society.

Entities:  

Keywords:  SDF-1/CXCL12; brain injury; cell proliferation; cell signalling; chemokines; chemotaxis

Mesh:

Substances:

Year:  2013        PMID: 23289420     DOI: 10.1111/nan.12015

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  14 in total

1.  Central SDF-1/CXCL12 expression and its cardiovascular and sympathetic effects: the role of angiotensin II, TNF-α, and MAP kinase signaling.

Authors:  Shun-Guang Wei; Zhi-Hua Zhang; Yang Yu; Robert B Felder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

2.  Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia.

Authors:  Jennifer S Yokoyama; Celeste M Karch; Chun C Fan; Luke W Bonham; Naomi Kouri; Owen A Ross; Rosa Rademakers; Jungsu Kim; Yunpeng Wang; Günter U Höglinger; Ulrich Müller; Raffaele Ferrari; John Hardy; Parastoo Momeni; Leo P Sugrue; Christopher P Hess; A James Barkovich; Adam L Boxer; William W Seeley; Gil D Rabinovici; Howard J Rosen; Bruce L Miller; Nicholas J Schmansky; Bruce Fischl; Bradley T Hyman; Dennis W Dickson; Gerard D Schellenberg; Ole A Andreassen; Anders M Dale; Rahul S Desikan
Journal:  Acta Neuropathol       Date:  2017-03-07       Impact factor: 17.088

3.  Inhibiting the Migration of M1 Microglia at Hyperacute Period Could Improve Outcome of tMCAO Rats.

Authors:  Ming Huang; Yan Wan; Ling Mao; Quan-Wei He; Yuan-Peng Xia; Man Li; Ya-Nan Li; Hui-Juan Jin; Bo Hu
Journal:  CNS Neurosci Ther       Date:  2016-12-19       Impact factor: 5.243

Review 4.  Functions of the chemokine receptor CXCR4 in the central nervous system and its regulation by μ-opioid receptors.

Authors:  Bradley Nash; Olimpia Meucci
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

5.  A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.

Authors:  Kuo-Jen Wu; Seong-Jin Yu; Kak-Shan Shia; Chien-Huang Wu; Jen-Shin Song; Hsuan-Hao Kuan; Kai-Chia Yeh; Chiung-Tong Chen; Eunkyune Bae; Yun Wang
Journal:  Cell Transplant       Date:  2016-10-27       Impact factor: 4.064

6.  Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.

Authors:  Laura Mercurio; Maria Antonietta Ajmone-Cat; Serena Cecchetti; Alessandro Ricci; Giuseppina Bozzuto; Agnese Molinari; Isabella Manni; Bianca Pollo; Stefania Scala; Giulia Carpinelli; Luisa Minghetti
Journal:  J Exp Clin Cancer Res       Date:  2016-03-25

7.  Administration of BMSCs with muscone in rats with gentamicin-induced AKI improves their therapeutic efficacy.

Authors:  Pengfei Liu; Yetong Feng; Chao Dong; Dandan Yang; Bo Li; Xin Chen; Zhongjun Zhang; Yi Wang; Yulai Zhou; Lei Zhao
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

8.  Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells.

Authors:  Susan Louise Lindsay; Steven Andrew Johnstone; Michael Anthony McGrath; David Mallinson; Susan Carol Barnett
Journal:  Stem Cell Reports       Date:  2016-04-21       Impact factor: 7.765

9.  CXCL12-induced rescue of cortical dendritic spines and cognitive flexibility.

Authors:  Lindsay K Festa; Elena Irollo; Brian J Platt; Yuzen Tian; Stan Floresco; Olimpia Meucci
Journal:  Elife       Date:  2020-01-23       Impact factor: 8.140

10.  Protective Effect of CXCR4 Antagonist CX807 in a Rat Model of Hemorrhagic Stroke.

Authors:  Seong-Jin Yu; Kuo-Jen Wu; Yu-Syuan Wang; Jen-Shin Song; Chien-Huang Wu; Jiing-Jyh Jan; Eunkyung Bae; Hsi Chen; Kak-Shan Shia; Yun Wang
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.